Wirewalk Instituteof AI
mfg-270 Intermediate AvailableFlagship

Building and Deploying AI in Pharma Manufacturing under GMP

For validation, MS&T, PAT, QA systems and data-integrity engineers at US drug manufacturers: you leave able to qualify, change-control and operate a specific AI model or AI feature on a GMP site in a way the quality unit can approve and an FDA investigator can follow.

Level
Intermediate
Study time
16 hours
Lessons
19 in 6 modules
Exam
20 questions

About this course

AI on a GMP site rarely fails because the model is weak. It fails at a specific step in a specific job: a visual inspection model that looks accurate overall but misses glass particles, a camera swap treated as "like for like" with no retest, a soft sensor placed in the control strategy with no independent check, a deviation summary pasted into the record without anyone checking it against the lab results, or an AI feature a SaaS supplier switched on in the last release. This course teaches those jobs one at a time. Each module follows a named role at a fictional US sterile-injectables and biologics site through the task as it is done today, where AI helps and where it must not, the data and systems actually involved (inspection machines, historians, PAT data managers, LIMS, CDS, MES/eBR and eQMS), the product categories and vendors used for that task as of October 2026, the controls that apply to that exact task, how to measure success, and a hands-on exercise with synthetic data for fictional products such as "Examplol 10 mg/mL injection" and "mAb-X".

US rules set the decision boundary throughout: 21 CFR 211.22, 211.68, 211.100, 211.110, 211.180(e), 211.188 and 211.192, 21 CFR Part 11, FDA's April 2026 warning letter citing inappropriate use of AI to write specifications and master records, FDA's January 2025 draft guidances on AI credibility for drug regulatory decision-making and on complying with 211.110, the 2011 Process Validation guidance, the 2018 Data Integrity Q&A, ICH Q9(R1), Q10, Q13, Q2(R2) and Q14, and ISPE GAMP 5 Second Edition with the 2025 GAMP Guide: Artificial Intelligence. FDA's 2025 Computer Software Assurance guidance is taught as device guidance applied to drug systems by analogy only. EU GMP Annex 1 appears because it binds sites that supply the EU market. The July 2025 consultation drafts of EU GMP Annex 22 "Artificial Intelligence" and the revised Annex 11 bind no one; they are taught, labeled as drafts, as signals of where EU and PIC/S expectations are heading, and Annex 22's scope is under revision. Vendor products are named to show the tool categories in use, not as endorsements, and no vendor performance claims are taught as fact. This course is educational, not legal or regulatory advice; leaders take hls-530.

What you will be able to do

  • Classify a proposed GMP AI use as critical or non-critical by rating model influence and decision consequence with FDA's seven-step credibility framework, and name the 21 CFR 211 and Part 11 sections that already govern it
  • Write the intended-use statement, subgroup list and per-subgroup acceptance criteria for a deep-learning visual inspection recipe, and find the subgroup that fails in a synthetic 600-container test set even though overall accuracy passes
  • Specify test-data independence, confidence-threshold and "undecided" routing controls for a critical vision model, consistent with Annex 1 section 8.32 and draft Annex 22 sections 6 and 9
  • Write a change-control impact assessment for a camera or container-supplier change on a validated model, justify retest versus retrain, and define two drift metrics with alert and action limits
  • Build a PCA batch model with Hotelling T2 and SPE limits on synthetic fed-batch data, find the planted abnormal batches, and draft the CPV signal-response procedure that links to 211.192 investigations
  • Fit a PLS soft sensor on synthetic spectra, flag out-of-model-space samples from a new excipient lot, and write the control-strategy paragraph that pairs a process model with in-process testing of the material, as the 211.110 draft expects
  • Score an LLM deviation summarizer for groundedness on a synthetic evaluation set and write the configuration, review and Part 11 audit-trail controls for its use
  • Risk-assess AI features in a synthetic SaaS release note against supplier-oversight expectations, build audit-trail and review-by-exception flags measured by recall on seeded events, and document what a qualified person still reviews

Syllabus

6 modules · 19 lessons · about 16 hours

Module 1: MS&T Writer and Quality Unit Approver: The CGMP Rules That Already Govern AI, Starting With an AI-Drafted Batch Record

Before any model is built, the quality unit decides whether a use is critical, which existing CGMP sections apply and who signs for AI output, using FDA's 2026 warning letter on AI-written records as the running case.
3 lessons
  1. What 211.22, 211.68, 211.100, 211.110, 211.192 and Part 11 Already Require of AI, and What FDA's April 2026 Purolea Warning Letter Shows
  2. Critical or Non-Critical: Rating Model Influence and Decision Consequence With FDA's Seven-Step Credibility Framework and Draft Annex 22 Section 1
  3. Reviewing an AI-Drafted Master Production Record Section Against a Tech-Transfer Summary: Eight Planted Errors and the SOP Clause for AI-Assisted Drafting

Module 2: Automation and Validation Engineer: Qualifying a Deep-Learning Visual Inspection Recipe for Parenteral Containers

Taking a deep-learning inspection recipe for a viscous Examplol vial line from defect library to an acceptance test that shows it is equal to or better than qualified manual inspectors for every defect class.
3 lessons
  1. Intended Use, Defect Library and Subgroups for the Examplol 10 mg/mL Vial Line Under Annex 1 Section 8.30 and Draft Annex 22 Section 3
  2. Acceptance Criteria Against the Manual Baseline: Per-Subgroup Sensitivity and Specificity on 600 Synthetic Containers, and the Subgroup That Fails
  3. Test-Set Independence, Heat Maps, Confidence Thresholds and the Undecided Route, Compared With FDA's Drug B Fill-Level Example

Module 3: Data Scientist, CSV Lead and CMC Regulatory Scientist: Change Control and Lifecycle Maintenance for a Validated Model

Deciding what a new camera and a new glass supplier mean for the qualified inspection model, catching silent degradation with drift monitoring, and describing the model's lifecycle plan in the PQS and in a supplement.
3 lessons
  1. Impact Assessment for a Camera Replacement and a New Glass Supplier: Retest, Retrain or Justify Under Draft Annex 22 Section 10 and FDA's Lifecycle Section
  2. Configuration Control and Drift Monitoring: Model Version Hashes, Input-Brightness Shift and Per-Class Reject Charts Over Eight Synthetic Weeks
  3. Writing the Credibility Assessment and Lifecycle-Maintenance Summary for a Model in the Control Strategy

Module 4: MS&T/CPV Engineer and PAT Scientist: Multivariate Batch Monitoring and Soft Sensors That Do Not Stand Alone

Building a Stage 3 CPV batch-evolution model and a Raman/NIR soft sensor for in-process control, then writing them into procedures and a control strategy that pairs every process model with testing or monitoring that does not share its assumptions.
4 lessons
  1. Building a PCA Batch Model With T2 and SPE Limits on 40 Synthetic mAb-X Fed-Batch Runs (SIMCA-online, Aspen ProMV and Python)
  2. From Signal to Investigation: Contribution Plots, the CPV Signal-Response Procedure, 211.192 and the Annual Product Review Under 211.180(e)
  3. A PLS Soft Sensor on Synthetic Spectra: RMSEP, Out-of-Model-Space Diagnostics and Twenty Samples From a New Excipient Lot
  4. Why Control Strategies That Rely Solely on Process Models Are Insufficient: Writing the 211.110 Pairing and Model Maintenance Into the Control Strategy

Module 5: QA Systems Owner and CSV/CSA Lead: AI Features Inside the eQMS and Other Validated SaaS

Deciding which supplier-released AI features to enable, configuring an LLM deviation and CAPA summarizer that never assigns root cause, and proving with an evaluation set that its drafts stay grounded in the record.
3 lessons
  1. Five AI Features in a Synthetic SaaS Release Note: Intended Use, Risk, Supplier Questions and CSA Thinking Applied to Drug Systems by Analogy
  2. Configuring a Deviation and CAPA Summarizer (Veeva QMS Deviation Agent, MasterControl Event Summarizer): What It May Draft and What It May Not Decide
  3. A Groundedness Evaluation Set for a Synthetic Examplol Fill-Weight Deviation Pack, and Recording AI Text and Human Edits Under Part 11

Module 6: QC Data-Integrity Lead and MES Engineer: Risk-Based Audit-Trail Review and Batch Record Review by Exception

Ranking CDS and LIMS audit-trail entries and eBR events for human review with rules plus anomaly scores, measured by recall on seeded high-risk events, without ever hiding a required review.
3 lessons
  1. Rules Plus an Anomaly Score Over a Synthetic 5,000-Line CDS Audit Trail With 12 Seeded High-Risk Events, Measured by Recall
  2. Adding ML Anomaly Flags to eBR Review by Exception: URS Lines, Rule Exceptions That Cannot Be Suppressed, and 211.188 and 211.192
  3. Classifying Deviations and Complaints for Trending: Agreement With a Dual-Coded Set, Rare-Category Recall and Rerun Stability

Exam and certificate

The exam unlocks once you have completed every lesson. It draws 20 questions from a larger bank, spread across the modules, with the answer options shuffled for each attempt. You have 40 minutes and need 80% to pass. After a failed attempt you can try again after 24 hours, up to 3 attempts in total. Feedback is given per module, never as the answer key.

Passing earns a certificate of completion and assessment from the Wirewalk Institute of AI with a unique ID that anyone can check at institute.wirewalk.com/verify. It is not an accredited qualification or a vendor certification. How certification works.

The Wirewalk Institute of AI is independent. This course teaches publicly documented products and is not affiliated with or endorsed by Syntegon, Sartorius, AspenTech (Emerson), Siemens, Veeva Systems, MasterControl, Stevanato Group, Körber, Antares Vision, Emerson, AVEVA, Waters, Thermo Fisher Scientific, LabWare, LabVantage, or TetraScience. Product and company names are trademarks of their respective owners.

More in AI in Manufacturing and Industrial Operations

All 16 courses in this track
mfg-001 Free intro Available

AI in Manufacturing and Industrial Operations: The One-Hour Briefing

A free hour built around real plant jobs: a maintenance planner turning overnight vibration alerts into work orders, a technician diagnosing a drive fault with a manual-citing copilot without touching lockout/tagout, a quality engineer setting the threshold on an AI terminal-lock vision check, an OT engineer deciding read-only versus write-back for a vendor's cloud link, a machine-safety engineer classifying ML person detection, and a pharma QA specialist drafting a deviation summary under human review.

1 h · 8 lessons Free intro
mfg-110 Basic Available

AI for Manufacturing and Plant Professionals

Practice with a fictional Ohio components plant using complete inline records. Check AI summaries, quality-review metrics, maintenance evidence, schedule feasibility and controlled-document claims before recommending a bounded next step.

8 h · 18 lessons See price at checkout
mfg-210 Intermediate Available

Building and Deploying AI in Industrial Operations

Evaluate plant AI through a cumulative synthetic US food-manufacturing case: data lineage, alert-to-work-order evidence, causal soft sensors, controlled-document RAG, control-model tests and read-only gateways. Assemble a reviewable decision dossier; no production authority or safety qualification is granted.

22 h · 23 lessons See price at checkout